Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce

Kathryn Connelly; Cristina Vazquez‐Mateo; Alessandro Sorrentino; Ronald van Vollenhoven; Kenneth Kalunian; Anna Stevens; Youmna Lahoud; Cynthia Aranow; Yoshiya Tanaka; Hermine I. Brunner; Edward M Vital; C. Stach; Guillermo Pons‐Estel; Victoria P. Werth; Patrick Marquis; Maria Dall’Era; Jeanette Andersen; Nikolay Delev; Eric F. Morand; Ying Sun; Eve Smith; Qing Zuraw; Rachel Koelmeyer; George Stojan; Vera Golder; Sandra Garcês; Catherine Barbey; Alain Cornet; Cailin H. Sibley; Darshini Ayton; Justine Maller; Laurie B. Burke; Richard Furie; Rangi Kandane‐Rathnayake; Erika H. Noss; Laurent Arnaud; Laura Eades; Lee S. Simon; Anca Askanase; Khadija Dantata; Tim Coulom; Kate Gregory; Alan Friedman; Maya Hojnik; Joy Buie; J Terés; Elaine Karis

doi:10.1038/s41584-023-00993-7

Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce

Kathryn Connelly(Monash Health), Cristina Vazquez‐Mateo(Amgen (United States)), Alessandro Sorrentino(AstraZeneca (United Kingdom)), Ronald van Vollenhoven(Amsterdam University Medical Centers), Kenneth Kalunian(University of California, San Diego), Anna Stevens(Bristol-Myers Squibb (United States)), Youmna Lahoud(Biogen (United States)), Cynthia Aranow(Feinstein Institute for Medical Research), Yoshiya Tanaka(University of Occupational and Environmental Health Japan), Hermine I. Brunner(Cincinnati Children's Hospital Medical Center), Edward M Vital(University of Leeds), C. Stach(Merck KGaA, Darmstadt (Germany)), Guillermo Pons‐Estel(Hospital Provincial de Rosario), Victoria P. Werth(Philadelphia VA Medical Center), Patrick Marquis(Northern General Hospital), Maria Dall’Era(University of California, San Francisco), Jeanette Andersen, Nikolay Delev(Bristol-Myers Squibb (Sweden)), Eric F. Morand(Novartis (Switzerland)), Ying Sun(Qingdao University), Eve Smith(University of Liverpool), Qing Zuraw(Janssen (United States)), Rachel Koelmeyer(Monash Health), George Stojan(UCB Pharma (Belgium)), Vera Golder(Monash University), Sandra Garcês(Amgen (United States)), Catherine Barbey(Biogen (Switzerland)), Alain Cornet, Cailin H. Sibley(Janssen (United States)), Darshini Ayton(Australian Regenerative Medicine Institute), Justine Maller, Laurie B. Burke(Center for Drug Evaluation and Research), Richard Furie(Hofstra University), Rangi Kandane‐Rathnayake(Monash University), Erika H. Noss(Brigham and Women's Hospital), Laurent Arnaud(Université Libre de Bruxelles), Laura Eades(Monash Health), Lee S. Simon(Norfolk and Norwich University Hospital), Anca Askanase(Columbia University Irving Medical Center), Khadija Dantata(Lupus Foundation of America), Tim Coulom(Eli Lilly (United States)), Kate Gregory(Monash Health), Alan Friedman(AbbVie (United States)), Maya Hojnik(Eli Lilly (United States)), Joy Buie(Lupus Foundation of America), J Terés, Elaine Karis(Amgen (United States))

Nature Reviews Rheumatology

July 11, 2023

10.1038/s41584-023-00993-7

Cited by 29

Related Papers

Core outcome domains for chronic pain clinical trials: IMMPACT recommendations

|Pain|2003|3.5k

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

|Annals of the Rheumatic Diseases|2020|2.8k

Trial of Anifrolumab in Active Systemic Lupus Erythematosus

|New England Journal of Medicine|2019|1.3k

Content Validity—Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product Evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 2—Assessing Respondent Understanding

|Value in Health|2011|1.1k

Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis

|New England Journal of Medicine|2005|1.1k